Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06157151 · ClinicalTrials.gov registry record · Phase 2
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
A Phase 2 study of Cervical Cancer and HPV-Related Carcinoma, sponsored by Precigen.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 3
- Study locations
NCT06157151: Recruiting Phase 2 study of Cervical Cancer and HPV-Related Carcinoma, sponsored by Precigen.
NCT06157151 is a Phase 2 study of Cervical Cancer and HPV-Related Carcinoma that is actively recruiting participants, run by Precigen. The registered enrollment target is 46 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06157151, a Phase 2 study of Cervical Cancer and HPV-Related Carcinoma, is actively recruiting participants, sponsored by Precigen.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 3
- Study locations
Study Summary
This randomized trial will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab compared to pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.
Primary Outcome
The ORR will be calculated as the combination of subjects achieving a complete response or a partial response per RECIST v1.1. ORR will be calculated and presented with 2-sided 95% confidence interval.
Conditions Studied
Interventions
- BIOLOGICAL PRGN-2009 plus Pembrolizumab
- DRUG Pembrolizumab alone
Study Locations (3)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Maryland
- National Institute of Health - Bethesda
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2025-03-21 |
| Est. Completion | 2028-01-30 |
| Phase | Phase 2 |
What NCT06157151 shows while recruiting
NCT06157151 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (92% lower).
The record links to 5 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 2 interventions - of which PRGN-2009 plus Pembrolizumab is the first listed.
NCT06157151 reports a single indexed study location in Arkansas, Maryland, Washington.
Frequently Asked Questions
What is clinical trial NCT06157151 about?
NCT06157151 is a clinical study titled "PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer". This randomized trial will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab compared to pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.
What is the current status of trial NCT06157151?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2025-03-21. Estimated completion is 2028-01-30.
What conditions does trial NCT06157151 study?
This clinical trial studies the following conditions: Cervical Cancer, HPV-Related Carcinoma, Recurrent Cervical Carcinoma, HPV-Related Malignancy, Metastatic Cervical Cancer.
What interventions are being tested in trial NCT06157151?
The interventions under investigation include: PRGN-2009 plus Pembrolizumab (BIOLOGICAL), Pembrolizumab alone (DRUG).
Who is sponsoring clinical trial NCT06157151?
This trial is sponsored by Precigen, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06157151 being conducted?
This trial has 3 study locations across Arkansas, Maryland, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06157151's enrollment target sits among peer trials
46 103rd of 144 higher than 42 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
RECRUITING · Phase 2
-
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
RECRUITING · Phase 2
-
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI